An independent study published online in the journal Urology found that minimally invasive surgery for prostate cancer significantly reduces complications when compared to open surgery. The study found that minimally invasive surgery for prostate cancer, including laparoscopic and robotic-assisted surgery, was associated with lower transfusion rates, shorter length of hospital stay, and lower serious postoperative complication and mortality rates compared to open prostatectomy.

Aethlon Medical (San Diego) reported the formal launch of Exosome Sciences (ESI), a wholly-owned subsidiary previously established by to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions.